CA Patent

CA2570096A1 — Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-one

Assigned to Abbott Healthcare Products BV · Expires 2006-01-19 · 20y expired

What this patent protects

The present invention relates to an extended release formulation of 3-amino-8-(1­piperazinyl)-2H-1-benzopyran-2-one or a pharmaceutically acceptable salt thereof or a hydrate of said pharmaceutically acceptable salt thereof. The invention further relates to the preparation of the…

USPTO Abstract

The present invention relates to an extended release formulation of 3-amino-8-(1­piperazinyl)-2H-1-benzopyran-2-one or a pharmaceutically acceptable salt thereof or a hydrate of said pharmaceutically acceptable salt thereof. The invention further relates to the preparation of these extended release formulations and their use in the prevention or treatment of disorders, especially pain and CNS disorders such as depression, anxiety and movement disorders.

Drugs covered by this patent

Patent Metadata

Patent number
CA2570096A1
Jurisdiction
CA
Classification
—
Expires
2006-01-19
Drug substance claim
No
Drug product claim
No
Assignee
Abbott Healthcare Products BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.